Structural Variations of the Cell Wall Precursor Lipid II and Their Influence on Binding and Activity of the Lipoglycopeptide Antibiotic Oritavancin

Peptidoglycan Cross-Linking in Glycopeptide-Resistant Actinomycetales

(2014) Jean-Emmanuel Hugonnet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery

(2013) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The functionalvanGCdcluster ofClostridium difficiledoes not confer vancomycin resistance

(2013) Fariza Ammam et al.   MOLECULAR MICROBIOLOGY

Combining biocatalysis and chemoselective chemistries for glycopeptide antibiotics modification

(2012) Tsung-Lin Li et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Fourteen years in resistance

(2012) David M. Livermore   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The Nonantibiotic Small Molecule Cyslabdan Enhances the Potency of β-Lactams against MRSA by Inhibiting Pentaglycine Interpeptide Bridge Synthesis

(2012) Nobuhiro Koyama et al.   PLoS One

Identification and in vitro Analysis of the GatD/MurT Enzyme-Complex Catalyzing Lipid II Amidation in Staphylococcus aureus

(2012) Daniela Münch et al.   PLoS Pathogens

Self-Resistance and Cell Wall Composition in the Glycopeptide Producer Amycolatopsis balhimycina

(2011) Till F. Schäberle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

(2010) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus

(2010) Oscar Domenech et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

(2010) B. P. Howden et al.   CLINICAL MICROBIOLOGY REVIEWS

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

(2010) Louis D. Saravolatz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The Lipopeptide Antibiotic Friulimicin B Inhibits Cell Wall Biosynthesis through Complex Formation with Bactoprenol Phosphate

(2009) T. Schneider et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

(2009) F. F. Arhin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications

(2009) Siegfried S.F. Leung et al.   BIOORGANIC & MEDICINAL CHEMISTRY

An oldie but a goodie – cell wall biosynthesis as antibiotic target pathway

(2009) Tanja Schneider et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

(2009) G. A. McKay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium

(2009) Gary J. Patti et al.   JOURNAL OF MOLECULAR BIOLOGY

Oritavancin Binds to Isolated Protoplast Membranes but not Intact Protoplasts of Staphylococcus aureus

(2009) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY

Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus

(2008) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

(2008) Alicia I. Hidron et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus

(2008) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY

The bacterial envelope as a target for novel anti-MRSA antibiotics

(2008) Françoise Van Bambeke et al.   TRENDS IN PHARMACOLOGICAL SCIENCES